Month: August 2025
Istaroxime was added to currently available inotropes and vasopressors in the study – no new safety signals were identified and physiological improvements were consistent with istaroxime responses in previous trials Cardiogenic shock is a severe presentation of heart failure and SCAI Stage C patients have low blood pressure and signs of organ damage due to…
Read More
Clinical proof-of-concept achieved in Phase 1A study for FX-909, a first-in-class orally available small molecule inhibitor of PPARG Excerpt from the Press Release: CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) — Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced that…
Read More
Excerpt from the Press Release: BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) — Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of patients with cardiovascular diseases, today announced that it has completed enrollment in two global, multi-center, Phase 2 clinical trials assessing the safety and efficacy of CRD-750 in…
Read More
Appointments reflect ARTBIO’s commitment to utilizing world-class experience and insights needed to advance alpha radioligand programs Company Co-founder Roy Larsen, Ph.D. will transition from Board of Directors to a new Technical Advisory Board within ARTBIO Excerpt from the Press Release: CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ — ARTBIO, Inc. (“ARTBIO”), a clinical-stage radiopharmaceutical company developing a…
Read More
Leaders in pioneering cancer diagnostics and NGS target enrichment technologies join forces to accelerate access to advanced molecular diagnostics for cancer Excerpt from the Press Release: FREMONT, Calif. and TAIZHOU, China, July 30, 2025 (GLOBE NEWSWIRE) — Paragon Genomics, Inc., a global leader in target enrichment solutions for next-generation sequencing (NGS), and Genecast (Taizhou) Biotechnology…
Read More
Patent Strengthens International Protection for First-of-Its-Kind Immunopreventive Platform Expands Global IP Coverage in Markets with High Incidence of Breast Cancer Excerpt from the Press Release: SAN JOSE, Calif., July 30, 2025 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced…
Read More
Excerpt from the Press Release: NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain–(BUSINESS WIRE)–Prilenia Therapeutics B.V. and Ferrer today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the refusal of the marketing authorization for pridopidine’s marketing authorization application for Huntington’s disease (HD). We are disappointed, but…
Read More
Excerpt from the Press Release: NEWTON, Mass., July 28, 2025 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced results showing that implementing a blood-based pTau217 screening assay reduced Acumen’s overall clinical trial…
Read More
Enrollment in Both Dose Cohorts of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrophic Cardiomyopathy (HCM) Complete; Follow-up Data from Cohort 1 and Initial Data from Cohort 2 Expected in Fourth Quarter of 2025 First Patient Dosed in 6E13 vg/kg Cohort 2 of RIDGE™-1 Phase 1b Clinical Trial of TN-401 for Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)…
Read More Potent TCR-mimetic CD3 T-cell engaging antibody targets peptide HLA complexes from TERT, a broadly expressed tumor antigen Preclinical studies demonstrate strong efficacy and a favorable safety profile Nomination expands Crossbow’s pipeline and reinforces the scalability of its T-Bolt™ platform to treat a wide range of cancers Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Crossbow Therapeutics,…
Read More- « Previous
- 1
- 2
- 3
- Next »